Published in Clin Cancer Res on September 17, 2015
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J (2016) 0.75
Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci (2017) 0.75
Hippo pathway regulates neural stem cell quiescence. Cell Cycle (2016) 0.75
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer (2007) 5.78
Hippo signaling: growth control and beyond. Development (2011) 5.25
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell (2011) 4.85
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell (2010) 4.49
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev (2012) 3.48
TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol (2008) 3.44
Hippo pathway regulation by cell morphology and stress fibers. Development (2011) 2.94
Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol (2014) 2.84
A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J (2008) 2.46
The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol (2012) 2.21
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res (2011) 2.21
A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem (2011) 2.00
Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem (2012) 1.89
YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One (2014) 1.82
Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene (2002) 1.82
A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J (2012) 1.81
Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One (2013) 1.81
Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell (2013) 1.78
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell (2014) 1.68
The Crumbs complex: from epithelial-cell polarity to retinal degeneration. J Cell Sci (2009) 1.65
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal (2014) 1.61
Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci U S A (2013) 1.59
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene (2014) 1.44
LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res (2011) 1.32
Regulation of the Hippo pathway by cell architecture and mechanical signals. Semin Cell Dev Biol (2012) 1.20
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res (2013) 1.18
Integration of intercellular signaling through the Hippo pathway. Semin Cell Dev Biol (2012) 1.14
Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med (2009) 1.14
Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol (2012) 1.09
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget (2014) 1.03
SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene (2013) 1.03
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res (2014) 0.99
Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat Commun (2015) 0.98
The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res (2015) 0.97
Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur J Cancer (2013) 0.97
Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol (2013) 0.92
Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. Int J Cancer (2015) 0.90
Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci (2015) 0.89
The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol (2015) 0.88
Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol (2014) 0.87
RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res (2013) 0.84
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs (2013) 0.84
TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep (2014) 0.83
Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Sci Rep (2015) 0.81
Hypoxic conditions differentially regulate TAZ and YAP in cancer cells. Arch Biochem Biophys (2014) 0.80
Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther (2014) 0.79
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment. Ann Surg Oncol (2014) 0.78
Tumour suppressors: Hippo promotes microRNA processing. Nat Rev Cancer (2014) 0.76